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Abstract
Background: Human resource limitations are a challenge to the delivery of antiretroviral therapy (ART) in low-resource
settings. We conducted a cluster randomized trial to assess the effect of community-based peer health workers (PHW) on
AIDS care of adults in Rakai, Uganda.
Methodology/Principal Findings: 15 AIDS clinics were randomized 2:1 to receive the PHW intervention (n=10) or control
(n=5).PHW tasksincluded clinicandhome-based provisionof counseling,clinical,adherencetoART, and social support.Primary
outcomes were adherence and cumulative risk of virologic failure (.400 copies/mL). Secondary outcomes were virologic failure
ateach 24weektimepointupto192weeksofART.Analysiswasbyintention totreat.FromMay2006toJuly2008,1336patients
were followed. 444 (33%) of these patients were already on ART at the start of the study. No significant differences were found in
lack of adherence (,95% pill count adherence risk ratio [RR] 0.55, 95% confidence interval [CI] 0.23–1.35; ,100% adherence RR
1.10, 95% CI 0.94–1.30), cumulative risk of virologic failure (RR 0.81, 95% CI 0.61–1.08) or in shorter-term virologic outcomes (24
week virologic failure RR 0.93, 95% CI 0.65–1.32; 48 week, RR 0.83, 95% CI 0.47–1.48; 72 week, RR 0.81, 95% CI 0.44–1.49).
However,virologicfailurerates$96weeksintoARTweresignificantlydecreasedintheinterventionarmcomparedtothecontrol
arm (96 week failure RR 0.50, 95% CI 0.31–0.81; 120 week, RR 0.59, 95% CI 0.22–1.60; 144 week, RR 0.39, 95% CI 0.16–0.95; 168
week, RR 0.30, 95% CI 0.097–0.92; 192 week, RR 0.067, 95% CI 0.0065–0.71).
Conclusions/Significance: A PHW intervention was associated with decreased virologic failure rates occurring 96 weeks and
longer into ART, but did not affect cumulative risk of virologic failure, adherence measures, or shorter-term virologic
outcomes. PHWs may be an effective intervention to sustain long-term ART in low-resource settings.
Trial Registration: ClinicalTrials.gov NCT00675389
Citation: Chang LW, Kagaayi J, Nakigozi G, Ssempijja V, Packer AH, et al. (2010) Effect of Peer Health Workers on AIDS Care in Rakai, Uganda: A Cluster-
Randomized Trial. PLoS ONE 5(6): e10923. doi:10.1371/journal.pone.0010923
Editor: Patricia Kissinger, Tulane University, United States of America
Received December 30, 2009; Accepted May 12, 2010; Published June 2, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This study was funded by the Doris Duke Charitable Foundation, The Division of Intramural Research, The National Institute for Allergy and Infectious
Diseases, National Institutes of Health, and a National Institutes of Health Training Grant (2 T32-AI07291) and Career Development Grant (1 K23-MH086338). The
funders had no role in the study design, data collection and analysis, decision to publish, or preparation of this manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lchang8@jhmi.edu
Introduction
The provision of antiretroviral therapy (ART) in low-resource
settings entails substantial challenges due to human resource
limitations [1]. One of the main strategies advocated by the World
Health Organization (WHO) and the United States President’s
Emergency Plan for AIDS Relief (PEPFAR) to address this crisis is
through task shifting, the rational redistribution of tasks among
health workforce teams from higher trained providers to those who
require less training [2]. Community health workers (CHWs) are a
key cadre to whom tasks can be shifted; however, there is limited
trial-based evidence on their effectiveness in improving AIDS care
outcomes [2,3].
Community-based peer health workers (PHWs) are people
living with HIV (PLHIV) and may potentially be a valuable type of
CHW. Peers have been used effectively in HIV/AIDS programs
in low-resource settings, typically as peer educators [4], and
psychosocial support using peers has been recommended by the
WHO for all PLHIV [5]. However, PHWs could deliver more
care-oriented services in addition to counseling, education, and
social support, and may therefore provide one strategy to mitigate
the human resource crisis.
The Rakai Health Sciences Program (RHSP) is located in the
rural Rakai District in southwest Uganda. Since June 2004,
PEPFAR has enabled RHSP to provide ART via a decentralized,
mobile clinic approach. In an operational and implementation
research effort to evaluate the role of task shifting with PHWs at
RHSP [6,7], we conducted a cluster-randomised trial of the effect
of PHWs on adult AIDS care outcomes [8]. Descriptive pilot data
were previously presented [9], and this study reports trial
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in control communities, patients on ART in communities with
PHWs will have improved adherence and fewer virologic failures.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Ethics Statement
The trial was approved by institutional review boards at the
Uganda Virus Research Institute, the Uganda National Council
for Science and Technology, Johns Hopkins University, and the
Western Institutional Review Board (Olympia, WA). Informed
consent was not obtained for this study as the institutional review
boards agreed that (i) PHWs were program staff performing
routine care functions, and (ii) only de-identified programmatic
data would be analyzed by community of randomization, and
therefore no informed consent was required.
Study Setting
The Rakai district in southwestern Uganda has a population of
approximately 460,000 persons in an area of about 5000 square
kilometers. In June 2004, RHSP/PEPFAR began providing ART
through a mobile clinic program operating in 15 non-overlapping
catchment areas (clusters) throughout the district. The mobile
clinic model consisted of medical staff traveling from a central
facility to designated government health clinics in each catchment
area biweekly. In between clinic days (13 out of 14 days), patients’
options for accessing care were limited and included traveling to a
central facility, calling an RHSP mobile phone hotline (with call
cost paid by caller) or toll-free warmline (similar to a hotline but
staffed only during clinic hours), or visiting non-RHSP care
facilities and providers [10].
Participants
This trial was conducted between May 2006 to July 2008 and
comprised all adult patients at the 15 mobile clinic sites who were
either already on ART at the start of the trial or were started on
ART at any time during the trial. About half (53%) of these
patients were referred to the clinic from previous or current RHSP
studies. All of these studies have recruited participants represen-
tative of Rakai District as a whole [11]. The remaining
participants (47%) were ‘‘walk-ins’’ as any Rakai resident could
come to these clinics and receive HIV counseling, testing, and
care. Eligibility criteria for starting ART was a CD4 count #250
or WHO Stage IV illness [12]. All care and medications were
provided free of charge.
PHW Intervention (Arm A)
In addition to the usual standard of care at all clinic sites, Arm A
clinics received the PHW intervention. The general approach to
the design and implementation of this intervention was pragmat-
ically-oriented, meaning that a general framework for PHW
recruitment, training, tasks, and monitoring was developed, but
the intervention was allowed to adapt to needs and problems
which arose, e.g. arranging for a home visit to occur at a worksite
if so requested by a patient [8]. Criteria for becoming a PHW
included being a PLHIV on ART, good ART adherence for at
least six months, and literacy. PHWs were nominated by fellow
patients at each clinic site with final approval by RHSP staff if they
met all qualifications. PHWs received a two day residential
training on basic HIV pathogenesis, prevention, treatment,
adherence counseling, performing pill counts, protecting patient
confidentiality, and filling out a home visit form. Trainers included
RHSP staff and experienced PHWs from an urban-based
Ugandan ART program [13]. At the clinic, PHW tasks included
providing ART counseling and support in group and individual
sessions. For their home visit tasks, PHWs were initially assigned
about 15 patients each who were visited biweekly. At these visits,
PHWs were tasked to record on a standardized form a review of
symptoms, a patient self-report of adherence, and to perform and
record a pill count. PHWs were asked to counsel and educate their
patients on ART adherence and general HIV/AIDS-related issues
during these home visits. If patients were thought to need urgent
care, PHWs were asked to alert RHSP staff and facilitate transfer
to a higher level of care. PHWs returned completed forms to
subsequent clinic sessions where they were added to patient charts
for provider review. To assist with their duties and encourage
retention, PHWs were each given a bicycle, identifying t-shirts,
basic supplies, and an initial monthly allowance of about 12.5
USD. Day-to-day supervision of PHW activities were largely
performed by a single RHSP staff member working part-time.
Control Group (Arm B)
The control arm continued with the usual standard of care.
However, standard of care did change over the study period, as a
number of changes unrelated to the PHWs were subsequently
implemented by RHSP in both the PHW and control arms. These
programmatic changes included a peer educator program to
promote use of preventive care services in mid-2006, the use of
viral load results to guide care in late 2006, more focused ART-
related health messaging in early 2007, and the use of enhanced
adherence counseling, chart stickers to help identify patients failing
virologically, and second-line ART provider talks in mid- to late
2007.
Mobile Phone Support Intervention Substudy (Arm A
1
and A
2)
As a substudy, PHW intervention areas were also randomized
2:3 to receive a mobile phone support intervention (Arm A
1,n=4
clusters) or not (Arm A
2, n=6 clusters). PHWs randomized to the
mobile phone intervention were each given a mobile phone and,
in addition to their usual responsibilities, were tasked to use text
messaging to send home visit data back to the central clinic to be
reviewed by centralized staff. PHWs could also call providers with
questions or concerns [10]. Detailed results from this substudy will
be presented elsewhere.
Procedures
We used an unrestricted randomization process. The 15 mobile
clinic sites were randomized 2:1 to receive the PHW intervention
(Arms A, n=10 clusters) or control (Arm B, n=5 clusters). We
assigned clusters using unmatched, unrestricted random allocation
by a drawing of lots. Study investigators (LWC, JK) generated the
allocation sequence and implemented the randomization. This
study was open label and unblinded.
Outcomes
The primary outcomes included adherence (pill counts) and
cumulative risk of virologic failure (any failure during follow-up
period equaling failure). Secondary outcomes were virologic
failure at each 24 week time point up to 192 weeks of antiretroviral
therapy, mortality, lost to follow-up, and CD4 change at 24 and 48
weeks of ART. A summary clinic pill count was calculated by
dividing the number of pills taken over the study period by the sum
Peer Health Workers & AIDS
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analyzed dichotomously using two adherence cut points, 95% and
100% [14]. A patient self-report of adherence was also collected
with patients reporting medication doses missed over the three
preceding days at clinic visits. This self-report outcome was
analyzed dichotomously, i.e. any self-report of missed doses. Viral
loads (failure defined as .400 copies/mL) were measured at 24 to
192 week time points from antiretroviral therapy initiation by 24
week intervals. Progressively lower numbers of virologic outcomes
available for analyses over time resulted from administrative
censoring as patients started ART at different time points and only
outcomes occurring during the study period were analyzed. As
some patients began ART prior to the study period, these patients
may have had early virologic outcomes prior to the trial which
were not considered in analyses. Analyses were both stratified and
combined by patients initiating ART prior to the trial and
initiating during the trial. Viral loads were considered during the
study period if they were collected one month after the start of the
PHW intervention to help account for a ‘‘wash-out’’ period during
which viral loads would have been unlikely to be reflective of
intervention effects. Viral loads and CD4 counts were performed
every 24 weeks on all patients as part of routine patient monitoring
procedures. HIV viral loads were measured using the Amplicor
Monitor Assay, version 1.5 (Roche Diagnostics, Branchburg, NJ,
USA) with a lower limit of detection of ,400 copies/mL. CD4
cell counts were measured using FACSCount or FACSCalibur
(Becton Dickinson, San Jose, CA, USA). Patients were considered
lost to follow-up if they had not had a pharmacy visit for
medication pick-up in over 90 days. Mortality was ascertained
through verbal autopsies.
Statistical analysis
We originally estimated about 1000 patients would contribute
outcomes to this study and made our power calculations assuming
a 10:5 ratio of intervention to control clusters with balanced
numbers of participants in each cluster and no matching.
Assuming a 5% drop out rate, we anticipated approximately
4,909 person-weeks of follow-up information per cluster. Based on
previous RHSP studies, we used a 24 week virologic failure risk of
28% (i.e. a rate of about 0.0137 failures/person-week) and a
coefficient of variation (k) of 0.11 and intraclass correlation
coefficient (r) of 0.0024 [15,16]. With a two-sided alpha=0.05 and
1-B=0.80, comparing Arms A to B, the study was estimated to
have the power to detect a reduction in cumulative virologic
failure with a rate ratio of #0.74.
Efficacy analyses for cumulative risk of virologic failure and for
virologic outcomes at specific time points from ART initiation
were by intention to treat using log-binomial regression with
generalized estimating equations (GEE), an exchangeable corre-
lation structure, and robust variance estimates appropriate for
cluster-randomised trials [17]. To address potential concerns with
multiple testing, we conducted a global test for an overall
difference in relative risks across all time points between the two
arms using a GEE model with a Wald test statistic. Additionally,
we conducted trend analyses for differences in risks in the
intervention and control arm over time using interaction terms.
Finally, we conducted time to event analyses for first virologic
failure using Cox proportional hazards modeling corrected for
clustering. Because participants could have multiple episodes of
failure and suppression and analyses such as time to event did not
capture this clinical complexity, we focused on reporting the log-
binomial analysis at each time point from ART initiation. This
analysis allowed determination of risk ratios for all time points,
fully utilized all available data, and better reflected the clinical and
programmatic complexity of ART. Analyses were done with SAS
9.2 (SAS Institute Inc., Cary, NC) and STATA v10 (StataCorp,
College Station, TX).
Results
In April and May 2006, 19 PHWs were recruited, trained and
deployed at the ten intervention clinics; one to three PHWs were
assigned per clinic depending on patient load. Due to growing
patient numbers, a second group of 10 PHWs were deployed in
June 2007. Over the study period, the patient to PHW ratio grew
from a mean of around 15:1 (range 9–26:1) to about 28:1 (range
18–42:1). Process evaluations found that PHWs had visited 96% of
eligible patients at least once and ,1% of patients were known to
have refused PHW visits entirely. Based on completed home visit
forms, PHWs made about 11,768 home visits over 26 months,
averaging approximately 13 total visits per patient in the PHW
arm at a rate of about 1.1 visits per patient per month. Each PHW
visited approximately 5.4 patients per week.
Figure 1 shows the flow of participants through the study.
Figure 2 shows a map of the Rakai area and the clinic sites. At the
start of patient follow-up in May 2006, 444 active patients were
receiving ART through the RHSP/PEPFAR clinics (330 in Arm
A, 114 in Arm B). By the end of the study period in July 2008,
892 additional patients had been started on ART (640 in Arm A,
252 in Arm B), giving a total of 1336 patients (970 in Arm A, 366
in Arm B) with some follow-up during the study period. Table 1
shows enrollment characteristics. Sociodemographic characteris-
tics, immunologic and clinical stage of disease, the proportion of
patients on ART, the median duration of time patients were on
ART prior to the start of the trial, and the pre-trial 24 week and
48 week virologic failure rates appeared well balanced between
arms.
All 1336 patients had at least one adherence measure recorded,
and 957 had at least one routine viral load result performed during
the study period; 698/970 (72%) and 259/366 (71%) of patients in
Arms A and B respectively had virologic outcome data. Median
follow-up time for virologic outcomes in Arm A was 103 weeks per
participant (interquartile range [IQR], 97-111 weeks) and in Arm
B was 103 weeks (IQR, 94-113). Analyses of the primary outcome
of cumulative risk of virologic failure showed that 17.8% of
patients had at least one viral load failure in the PHW arm (124/
698) compared to 21.6% in the control arm (56/259) which was
nonsignificant (RR 0.81, 95% CI 0.61–1.08, p=0.16).
Table 2 shows the secondary outcomes of rates of virologic
failure during the study period by time on ART by 24 week
Figure 1. Trial profile.
doi:10.1371/journal.pone.0010923.g001
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affect virologic outcomes #72 weeks into ART, but failure rates
were generally lower in the intervention compared to the control
arm after $96 weeks of ART. In stratified analyses by whether
patients were initiated on ART before or after the start of the
trial, no significant effect of the PHW intervention was observed
among patients who initiated ART during the trial (all of whom
had been on ART ,120 weeks), but among those patients who
initiated ART prior to the trial (81% of whom had a viral load at
$120 weeks into ART), virologic failures were lower in the
intervention compared to the control arm at most testing intervals
$96 weeks.
A global test for overall difference in relative risks across all time
points was not significant (p=0.16). Subgroup analysis of patients
starting ART pre-trial showed a trend toward improved outcomes
(p=0.076) but analysis of those starting ART during the trial was
not significant (p=0.30). The trend analysis showed a statistically
significant decline in the risk of virologic failures over time for the
PHW arm compared to the control arm (p=0.016). More
specifically, in the PHW arm, the relative risk for virologic failure
during the $96 week period compared to the #72 week period
declined significantly (RR 0.44, 95% CI 0.24–0.78, p=0.005),
while in the control arm the relative risk trended in the opposite
direction (RR 1.47, 95% CI 0.90–2.40, p=0.12). Time to first
virologic failure analyses did not find a significant decrease in time
to first failure in the PHW arm (Hazard Ratio 0.82, 95% CI 0.56–
1.21, p=0.29). The intracluster correlation coefficient (ICC) for
virologic failure at 24 weeks was 0.0015 based on analyses of 929
patients.
Table 3 shows estimates of effect for non-virologic outcomes,
including the primary outcome of adherence. No significant
differences were noted for these outcomes except for lost to
follow-up rates which were improved in the PHW arm. Substudy
analysis of the mobile phone support intervention among the
PHWs found no statistically significant differences comparing
Arm A
1 to Arm A
2 for all virologic and non-virologic outcomes
(data not shown).
Discussion
This trial found that a PHW intervention was associated with
decreased virologic failure rates among patients on longer-term
ART ($96 weeks) with a significant trend of declining risk for
virologic failures over time compared to the control arm. The
PHW intervention was also associated with decreased lost to
follow-up rates but had no effect on cumulative risk of virologic
failure, virologic outcomes of patients on shorter-term ART, or
adherence measures.
Counseling and support during the early ART initiation period
was a major component of the PHW intervention, but these
interventions did not have a significant effect on virologic
outcomes of patients recently started on ART (#72 weeks). Our
study was originally powered to detect cumulative failure as a
primary outcome rather than failure at individual time points, the
rate of virologic failure was lower than anticipated, and virologic
outcomes were not available for about 28% of participants,
therefore this study was likely underpowered for these endpoints.
Also, early ART users are likely to be highly motivated, and the
PHW effect, if any, may be smaller during this period [18].
Additionally, the intensity of our intervention was less than we
initially desired, i.e. higher patient to PHW ratios and less frequent
home visits, which may have decreased the impact of the
intervention. Insufficient power also likely affected our ability to
detect differences with time to event analyses and global tests of
effect.
However, point estimates for virologic outcomes favored the
PHW Arm at all time points $96 weeks and generally trended
downward over time. Only one outcome at these time points, at
120 weeks, was not statistically significant, likely due to a lack of
power. This study did not find any differences in adherence, our
second primary outcome, which may reflect a lack of sensitivity of
our adherence measures. Lack of precision with self-report and
pill-count adherence measures has been noted before [14]. Our
number of outcomes for adherence ,95% was also small, further
complicating interpretation of these results. Loss to follow-up was
significantly decreased in the PHW arm, consistent with other
Figure 2. Map of cluster sites in Rakai, Uganda. Legend: Circles=Peer Health Worker Intervention Clinics (Arm A); Squares=Control Clinics (Arm
B); Thumbtack=Central Clinic.
doi:10.1371/journal.pone.0010923.g002
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of CHWs in encouraging patient retention [19,20].
The PHW association with improved virologic outcomes
occurring after relatively longer periods of ART and the significant
trend toward lower virologic failures over time suggest that PHWs
may mitigate the effects of ‘‘treatment fatigue’’ (i.e. patients tiring
of continually taking ART) [21]. Treatment fatigue may now
represent a significant barrier to the optimal maintenance of
effective ART in low-resource settings, and will likely grow in
importance as experience with ART continues to accumulate.
Notably, the PHW intervention effect was found only in patients
who initiated ART pre-trial in stratified analysis, i.e. the group on
ART longest, suggesting that this intervention may be best suited
for patients who have taken ART for longer periods and are prone
to treatment fatigue and its consequences.
Study limitations included its potentially limited generalisability
as it was undertaken in the setting of an atypical, mobile clinic
program nested in a long-standing research cohort. However, this
model of decentralized care may be increasingly adopted in rural
settings, and about half of patients in this ART program were
‘‘walk-ins’’ who had not previously participated in RHSP studies
[22]. For this trial, process evaluations were performed as has been
suggested is important to the understanding of complex interven-
tions such as ours [23]. These evaluations found that while PHWs
generally fulfilled their tasks, they did not visit patients as
frequently as initially planned which may have blunted the
intervention’s effects.
We encountered a number of challenges and issues which may
have relevance to the growing field of operations and implemen-
tation research in HIV/AIDS [6,7,24,25]. For example, we
disagree that there is no role for randomized trials in operations
research [7], but rather, pragmatically-oriented randomized trials
can be a useful study design to answer operations research
questions. Also, our study design was notably influenced by
Table 1. Characteristics according to randomization arm.*
Characteristic Subcharacteristic PHW Arm (A) Control Arm (B)
No clusters 10 5
No subjects total 970 366
No subjects per cluster, mean (range) 97 (47–163) 73 (33–116)
Female, n (%) 638 (65.8) 247 (67.5)
Age, median (range), years 35.5 (15–76) 34.0 (17–70)
Age group, n (%)
#29 244 (25.2) 102 (27.9)
30–39 435 (44.9) 163 (44.5)
$40 291 (30.0) 101 (27.6)
CD4 cell count at ART initiation, median (IQR), cells/ml 160 (77–217) 161 (78–216)
CD4 groups at ART initiation, n (%), cells/ml
,100 292 (30.1) 101 (27.7)
100–250 646 (66.6) 255 (69.9)
.250 32 (3.3) 9 (2.5)
Plasma HIV-1 RNA at ART initiation, geometric mean, copies/mL 44440 36047
Plasma HIV-1 RNA at ART initiation, mean (SD), log10 copies/mL 4.65 (0.93) 4.56 (0.87)
Baseline viral load .100,000 copies/mL, n (%) 421 (56.1) 167 (61.4)
Baseline WHO Stage, n (%)
1 287 (29.6) 106 (29.0)
2 349 (36.0) 140 (38.3)
3 224 (23.1) 89 (24.3)
4 109 (11.3) 31 (8.5)
Baseline ARV Regimen, n (%)
Combivir/Efavirenz 276 (28.5) 93 (25.5)
Combivir/Nevirapine 353 (36.4) 156 (42.7)
Stavudine/Lamivudine/Efavirenz 95 (9.8) 38 (10.4)
Stavudine/Lamivudine/Nevirapine 239 (24.6) 74 (20.3)
Other 7 (0.7) 4 (1.1)
Clinic distance to central clinic, mean (range), km 23.1 (7.7–40.5) 35.5 (8.6–54.5)
Subjects on ART prior to start of trial, n (%) 330 (34) 114 (31)
Subject pre-trial subject duration on ART, median (range), weeks 43.6 (1.0–89.4) 41.4 (0.6–89.6)
Pre-trial 24 week virologic failures, n/N (%) 85/191 (44.5%) 23/65 (35.4%)
Pre-trial 48 week virologic failures, n/N (%) 36/128 (28.1%) 12/46 (33.3%)
*PHW, Peer Health Worker; IQR, Interquartile Range; SD, Standard Deviation.
doi:10.1371/journal.pone.0010923.t001
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the randomization ratios were guided in part by programmatic
concerns, and we were not able to increase the number of PHWs
quickly enough to maintain our desired patient to PHW ratio.
Additionally, other programmatic interventions implemented
during the study period make interpretation of the effect of the
Table 2. Estimates of effect for virologic outcomes.*
PHW Arm (A)
Control Arm
(B) Arm A vs. B
Week x of ART
{ n failing/N % failing n failing/N % failing RR
{ 95% CI p value
All subjects
24 45/462 9.7 18/173 10.4 0.93 0.65–1.32 0.68
48 42/456 9.2 18/164 11.0 0.83 0.47–1.48 0.54
72 21/384 5.5 9/138 6.5 0.81 0.44–1.49 0.59
96 26/398 6.5 17/134 12.7 0.50 0.31–0.81 0.005
120 18/272 6.6 10/87 11.5 0.59 0.22–1.60 0.30
144 12/212 5.7 10/68 14.7 0.39 0.16–0.95 0.039
168 6/131 4.6 6/39 15.4 0.30 0.097–0.92 0.035
192 1/85 1.2 5/27 18.5 0.067 0.0065–0.71 0.024
Subjects initiating ART during trial
24 39/397 9.8 16/152 10.5 0.93 0.63–1.37 0.71
48 32/321 10.0 15/114 13.2 0.76 0.37–1.56 0.45
72 11/202 5.5 6/79 7.6 0.79 0.22–2.81 0.71
96 4/126 3.2 5/46 10.9 0.31 0.06–1.65 0.17
Subjects initiating ART pre-trial
24 6/65 9.2 2/21 9.5 1.04 0.30–3.58 0.95
48 10/135 7.4 3/50 6.0 1.11 0.63–1.97 0.70
72 10/182 5.5 3/59 5.1 1.10 0.32–3.71 0.89
96 22/272 8.1 12/88 13.6 0.58 0.34–0.99 0.045
120 18/272 6.6 10/87 11.5 0.59 0.22–1.60 0.30
144 12/212 5.7 10/68 14.7 0.39 0.16–0.95 0.039
168 6/131 4.6 6/39 15.4 0.30 0.097–0.92 0.035
192 1/85 1.2 5/27 18.5 0.067 0.0065–0.71 0.024
*PHW, Peer Health Worker; RR, Risk Ratio; CI, Confidence Interval.
{Viral loads were done routinely on all patients every 24 weeks. Viral load results were included in these analyses only if they were performed during the study period.
{Risk Ratio calculated using generalized estimating equations with robust variances.
doi:10.1371/journal.pone.0010923.t002
Table 3. Estimates of effect for non-virologic outcomes.*
Outcome
PHW Arm
(A)
Control Arm
(B) Arm A vs. B
N Outcome N Outcome Estimate (95% CI) p value
All subjects
,95% pill count adherence, n (%) 874 12 (1.4) 330 8 (2.4) 0.55
{ (0.23–1.35) 0.20
,100% pill count adherence, n (%) 874 223 (25.5) 330 77 (23.3) 1.10
{ (0.94–1.30) 0.23
Any missed doses self-report vs. never, n (%) 898 158 (17.6) 338 65 (19.2) 0.99
{ (0.96–1.02) 0.60
Died, n (%) 966 90 (9.3) 366 31 (8.5) 0.99
{ (0?96–1?03) 0.60
Lost to follow-up, n (%) 966 21 (2.2) 366 15 (4.1) 0.56
{ (0.36–0.88) 0.01
Subjects initiating ART during trial
CD4 Change at 24 weeks, mean (SD), cells/ml 415 155 (136) 156 157 (125) 21.9
{ (231.8228.0) 0.90
CD4 Change at 48 weeks, mean (SD), cells/ml 331 189 (143) 116 197 (154) 210.0
{ (237.9218.0) 0.49
*PHW, Peer Health Worker; CI, Confidence Interval; SD, Standard Deviation;
{Risk Ratios calculated from generalized estimating equations with robust variances;
{b1 from unadjusted general estimating equations model.
doi:10.1371/journal.pone.0010923.t003
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associations of the PHW intervention with improved virologic
outcomes in the setting of concurrent program improvements
would tend to provide further support for a real intervention effect.
Furthermore, this study highlights the complexities of analyzing
and understanding the effects of complex interventions imple-
mented in the midst of an ongoing care program. For example,
study patients initiated ART before and after the start of the
intervention, and PHWs may have different impacts on these types
of patients. Despite the challenges and limitations of this project,
we believe operations and implementation research endeavors can
result in important findings when pragmatically undertaken and
cautiously interpreted.
PHWs represent a potentially sustainable work force that is
unlikely to emigrate and able to remain proportional in size to the
HIV epidemic [26]. PHWs are consistent with the WHO task
shifting guidelines which encourage PLHIV to be part of the
health workforce crisis solution [2], and the promotion of the
greater involvement of PLHIV in their own care has been a
longstanding policy of WHO and UNAIDS [27]. Further research
on PHW processes, costs, training requirements, quality assurance,
and supervisory needs are warranted. We previously reported
early, rough costs of this intervention [9], and more rigorous cost
analyses are planned.
In conclusion, a community-based PHW intervention was
associated with decreased virologic failure rates occurring 96
weeks and longer into ART and decreased lost to follow-up rates
but did not have an effect on cumulative risk of virologic failure,
virologic outcomes of patients on shorter-term ART, or adherence
measures. PHWs may offer a pragmatic and effective strategy for
addressing the global human resource crisis in HIV/AIDS
programs and promoting long-term sustainability of ART in
low-resource settings.
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